Skip to main content
. 2017 Apr 13;7:46518. doi: 10.1038/srep46518

Table 2. Development of chronic kidney disease during follow-up.

  Overall (n = 587) Users of RAS inhibitor (n = 94) Non-users of RAS inhibitor (n = 493) P value
CKD development, N (%) 233 (39.7%) 25 (26.6%) 208 (42.2%) 0.005
Median CKD-free survival time, days 574 1079 520 0.011

Abbreviation: CKD, chronic kidney disease.